title: The risk and management of anaphylaxis in the setting of immunotherapy.
abstract: BACKGROUND
  Anaphylactic events due to immunotherapy are probably not completely preventable. There is always an inherent risk surrounding the administration of an allergen to an individual who is sensitized to the substance administered.
  
  
  METHODS
  There  are, however, effective measures to reduce the risk of these events, and to optimize the assurance of a good outcome in the face of such an event.
  
  
  RESULTS
  Of prime importance in preventing these episodes is the regular assessment of the patient's health status, especially  in regard to asthma, and the careful attention to the prevention of dosing errors.
  
  
  CONCLUSIONS
  Of equal importance, in regard to assuring a good outcome should such an event occur, are the rapid recognition of symptoms and the immediate injection of epinephrine, the drug  of choice for the treatment of any episode of anaphylaxis.
authors.affiliation: Allergy and Asthma Care, Germantown, Tennessee 38138, USA. Phillieberman@hotmail.com
authors.forename: Phil
authors.initials: P
authors.lastname: Lieberman
mesh_terms: D000707:Anaphylaxis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D004837:Epinephrine / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D015994:Incidence; D012306:Risk
chemical_list: D004837:Epinephrine